William Blair Comments on NuCana’s Q1 Earnings (NASDAQ:NCNA)

NuCana plc (NASDAQ:NCNA) – Research analysts at William Blair issued their Q1 2026 EPS estimates for NuCana in a report released on Thursday, March 20th. William Blair analyst M. Phipps expects that the company will earn ($0.01) per share for the quarter. The consensus estimate for NuCana’s current full-year earnings is ($13.42) per share. William Blair also issued estimates for NuCana’s Q2 2026 earnings at ($0.01) EPS, Q3 2026 earnings at ($0.01) EPS and Q4 2026 earnings at ($0.01) EPS.

NuCana (NASDAQ:NCNA) last posted its earnings results on Thursday, March 20th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.43) by $2.11.

NuCana Trading Up 1.3 %

NCNA opened at $0.80 on Monday. NuCana has a 12 month low of $0.69 and a 12 month high of $10.79. The stock has a 50-day moving average of $0.96 and a 200 day moving average of $1.49. The firm has a market cap of $2.11 million, a P/E ratio of -0.08 and a beta of 0.89.

Institutional Trading of NuCana

A number of institutional investors have recently bought and sold shares of NCNA. Two Sigma Securities LLC bought a new position in NuCana during the fourth quarter valued at $25,000. Citadel Advisors LLC bought a new stake in shares of NuCana in the 4th quarter worth about $30,000. Virtu Financial LLC purchased a new position in shares of NuCana during the 4th quarter worth about $48,000. Finally, Schonfeld Strategic Advisors LLC bought a new position in NuCana during the 4th quarter valued at about $54,000. 44.00% of the stock is currently owned by institutional investors.

About NuCana

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.